Aisling Capital Partners III LP
Insider CIK 1532634 · AGRX Director, 10% owner · ZLTQ 10% owner · TTOO 10% owner · VSAR 10% owner · DRTX 10% owner · SYRS 10% owner · LOXO 10% owner · SFES.OB 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| LOXO Loxo Oncology, Inc. | S Sale | 2018-07-10 | 2018-07-12 | 1,400,000 | $179.43 | $251.20M | 2,038,920 | SEC↗ |
| LOXO Loxo Oncology, Inc. | S Sale | 2017-12-19 | 2017-12-20 | 250,000 | $80.50 | $20.13M | 3,438,920 | SEC↗ |
| LOXO Loxo Oncology, Inc. | S Sale | 2017-11-22 | 2017-11-27 | 500,000 | $75.00 | $37.50M | 3,688,920 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2017-01-10 | 2017-01-12 | 160,000 | $31.00 | $4.96M | 4,188,920 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | C Conversion deriv | 2016-07-06 | 2016-07-06 | 1,907,122 | — | $0 | 0 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | C Conversion | 2016-07-06 | 2016-07-06 | 508,565 | — | $0 | 508,565 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | P Buy | 2016-07-06 | 2016-07-06 | 400,000 | $12.50 | $5.00M | 908,565 | SEC↗ |
| AGRX AGILE THERAPEUTICS INC | J Other | 2016-06-02 | 2016-06-03 | 400,000 | — | $0 | 2,583,797 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2016-05-17 | 2016-05-19 | 232,558 | $21.50 | $5.00M | 4,028,920 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2015-12-11 | 2015-12-15 | 200 | $27.50 | $5.5K | 3,796,362 | SEC↗ |
| TTOO T2 Biosystems, Inc. | P Buy | 2015-12-09 | 2015-12-09 | 307,692 | $9.75 | $3.00M | 2,830,992 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2015-11-17 | 2015-11-19 | 265,000 | $26.50 | $7.02M | 3,796,182 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2015-11-13 | 2015-11-16 | 1,955 | $27.47 | $53.7K | 3,531,182 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2015-11-12 | 2015-11-16 | 76,714 | $27.65 | $2.12M | 3,529,207 | SEC↗ |
| VSAR Versartis, Inc. | P Buy | 2015-01-27 | 2015-01-29 | 145,000 | $17.25 | $2.50M | 2,139,568 | SEC↗ |
| AGRX AGILE THERAPEUTICS INC | P Buy | 2015-01-23 | 2015-01-27 | 811,966 | $5.85 | $4.75M | 2,983,797 | SEC↗ |
| TTOO T2 Biosystems, Inc. | C Conversion deriv | 2014-08-12 | 2014-08-14 | 2,967,033 | — | $0 | 0 | SEC↗ |
| TTOO T2 Biosystems, Inc. | C Conversion deriv | 2014-08-12 | 2014-08-14 | 549,851 | — | $0 | 0 | SEC↗ |
| TTOO T2 Biosystems, Inc. | C Conversion | 2014-08-12 | 2014-08-14 | 2,068,755 | — | $0 | 2,068,755 | SEC↗ |
| TTOO T2 Biosystems, Inc. | P Buy | 2014-08-12 | 2014-08-14 | 454,545 | $11.00 | $5.00M | 2,523,300 | SEC↗ |
| LOXO Loxo Oncology, Inc. | C Conversion deriv | 2014-08-06 | 2014-08-06 | 506,960 | — | $0 | 0 | SEC↗ |
| LOXO Loxo Oncology, Inc. | C Conversion deriv | 2014-08-06 | 2014-08-06 | 2,343,749 | — | $0 | 0 | SEC↗ |
| LOXO Loxo Oncology, Inc. | C Conversion | 2014-08-06 | 2014-08-06 | 2,850,709 | — | $0 | 3,039,416 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2014-08-06 | 2014-08-06 | 413,077 | $13.00 | $5.37M | 3,452,493 | SEC↗ |
| DRTX Durata Therapeutics, Inc. | J Other | 2014-05-20 | 2014-05-22 | 3,528 | — | $0 | 0 | SEC↗ |
| DRTX Durata Therapeutics, Inc. | J Other | 2014-05-20 | 2014-05-22 | 745,730 | — | $0 | 2,280,175 | SEC↗ |
| TRXC TRANSENTERIX INC. | P Buy | 2014-04-21 | 2014-04-23 | 1,037,767 | $4.00 | $4.15M | 8,335,819 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion deriv | 2014-03-26 | 2014-03-27 | 14,222,222 | — | $0 | 0 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion deriv | 2014-03-26 | 2014-03-27 | 403,704 | — | $0 | 0 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion deriv | 2014-03-26 | 2014-03-27 | 1,479,993 | — | $0 | 0 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion deriv | 2014-03-26 | 2014-03-27 | 654,796 | — | $0 | 0 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion deriv | 2014-03-26 | 2014-03-27 | 5,486,820 | — | $0 | 0 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion | 2014-03-26 | 2014-03-27 | 1,236,715 | — | $0 | 1,271,819 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion | 2014-03-26 | 2014-03-27 | 35,104 | — | $0 | 35,104 | SEC↗ |
| VSAR Versartis, Inc. | P Buy | 2014-03-26 | 2014-03-27 | 60,000 | $21.00 | $1.26M | 1,994,568 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion | 2014-03-26 | 2014-03-27 | 477,115 | — | $0 | 1,934,568 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion | 2014-03-26 | 2014-03-27 | 56,939 | — | $0 | 1,457,453 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion | 2014-03-26 | 2014-03-27 | 128,695 | — | $0 | 1,400,514 | SEC↗ |
| DRTX Durata Therapeutics, Inc. | S Sale | 2014-03-21 | 2014-03-21 | 2,649 | $15.57 | $41.2K | 3,030,175 | SEC↗ |
| DRTX Durata Therapeutics, Inc. | S Sale | 2014-03-20 | 2014-03-21 | 98,000 | $15.74 | $1.54M | 3,032,824 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | J Other | 2014-01-23 | 2014-01-27 | 4,715 | — | $0 | 0 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | J Other | 2014-01-23 | 2014-01-27 | 994,305 | — | $0 | 2,597,742 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | J Other | 2014-01-23 | 2014-01-27 | 4,697 | — | $0 | 4,697 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | J Other | 2014-01-23 | 2014-01-27 | 2,398 | — | $0 | 2,398 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | J Other | 2014-01-23 | 2014-01-27 | 1,152 | — | $0 | 1,152 | SEC↗ |
| TRXC.OB TRANSENTERIX INC. | C Conversion | 2013-12-06 | 2013-12-10 | 12,401,764 | — | $0 | 36,490,260 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | S Sale | 2013-11-14 | 2013-11-15 | 575,000 | $12.22 | $7.03M | 3,597,742 | SEC↗ |
| SFES.OB SafeStitch Medical, Inc. | P Buy deriv | 2013-09-03 | 2013-09-05 | 1,240,176 | $4.00 | $4.96M | 1,240,176 | SEC↗ |
| TRXC.OB TRANSENTERIX INC. | C Conversion deriv | 2012-07-24 | 2013-12-10 | 1,240,176 | — | $0 | 0 | SEC↗ |
| DRTX Durata Therapeutics, Inc. | C Conversion deriv | 2012-07-24 | 2012-07-25 | 16,157,707 | — | $0 | 0 | SEC↗ |
| DRTX Durata Therapeutics, Inc. | P Buy | 2012-07-24 | 2012-07-25 | 1,111,111 | $9.00 | $10.00M | 3,130,824 | SEC↗ |
| DRTX Durata Therapeutics, Inc. | C Conversion | 2012-07-24 | 2012-07-25 | 2,019,713 | — | $0 | 2,019,713 | SEC↗ |